TerminatedNot Applicable

Cardiotoxic Effects of Chemotherapy in Patients With Sarcomas: A Two and Three-dimensional Echocardiographic Speckle Tracking Imaging Study

Stopped: Low accrual

United States400 participantsStarted 2016-01-20

Plain-language summary

This study is being done to identify markers that will allow researchers to identify in advance patients with sarcomas who are at highest risk for developing heart failure related to chemotherapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients followed at Mayo Clinic and treated for sarcoma with doxorubicin as first-line treatment Exclusion Criteria: * First-line treatment not including doxorubicin * Treatment performed outside of Mayo Clinic with different protocols * Age \< 18 years

What they're measuring

Changes in myocardial function - 2D-STE

Timeframe: Baseline, 3 months, 6 months, 1 year

Changes in myocardial function - 2D-STE vs 3D-STE

Timeframe: Baseline, 3 months, 6 months, 1 year

Changes in myocardial function - 2D-STE vs 2D-LVEF and 3D-LVEF

Timeframe: Baseline, 3 months, 6 months, 1 year

Changes in myocardial function - 2D-STE vs cardiac biomarkers

Timeframe: Baseline, 3 months, 6 months, 1 year

Trial details

NCT IDNCT06511388

SponsorMayo Clinic

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-10-09

View on ClinicalTrials.gov More Sarcoma trials